Earnings ·
Maravai LifeSciences Holdings, Inc. reported second quarter 2026 financial results on August 6, 2026
MRVIMaravai Lifesciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. reported second quarter 2026 financial results on August 6, 2026. Total revenue increased 8.5% year-over-year to $51.4 million, driven by an 11.5% rise in TriLink segment sales and a 2.8% increase in Cygnus segment sales. The company reported a net loss of $(21.6) million and positive Adjusted EBITDA of $8.7 million for the quarter. Management raised full-year 2026 Adjusted EBITDA guidance to $33 million–$35 million, up from the previous range of $30 million–$32 million, while reiterating revenue guidance of $205 million–$215 million. Maravai LifeSciences operates in the life sciences industry, providing reagents and services to researchers and biotech innovators.